Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof

US10526384B2 · kind B2 · utility

Assignee

• Pieris Pharmaceuticals GmbH · DE

Inventors

• Marlon Hinner · Freising, DE
• Laurent Audoly · Mahwah, US
• Martin Huelsmeyer · Freising, DE
• Kristian Jensen · Munich, DE
• Gabriele Matschiner · Munich, DE
• Shane Olwill · Freising, DE
• Alexander Wiedenmann · Ulm, DE
• Andrea Allersdorfer · Wolnzach, DE

Key dates

• Filing date: Nov 20, 2013
• Grant date: Jan 7, 2020
• Expiry date: Nov 20, 2033

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/54
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q16552 and novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q9NPF7. In addition, the present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against one or both of Swiss Prot Q16552 and Swiss Prot Q9NPF7. The invention also relates to nucleic acid molecules encoding such polypeptides and to methods for generation of such polypeptides and nucleic acid molecules. In addition, the invention is directed to compositions comprising the polypeptides, and therapeutic and/or diagnostic uses of these polypeptides.